Novo Nordisk 510620 manual Introduction

Page 7

Easy to change dose. The insulin dose can easily be changed without wasting insulin simply by dialling up or down.

Easy to change Penfill®. Innovo® is specially designed for the easy changing of Penfill® 3 ml cartridges and NovoFine® needles with a length of up to 8 mm. (Be sure to look for the s on the NovoFine® packaging when selecting needles).

Easy reminders. Innovo® has a battery that lasts for about 5 years from manufacturing date when used at a rate of four daily injections

INTRODUCTION

(including priming). After this time, the display flashes to tell you that Innovo® will expire.

Be sure to replace Innovo® within 30 days. The battery cannot be changed. This is to guarantee quality and safety at all times.

Thank you for choosing Innovo®. It is important that you follow the instructions carefully to make insulin therapy as easy to live with as possible.

Image 7

Contents Innovo Page Innovo Novo Nordisk A/S Contents Introduction Introduction Getting started Getting Started Getting Started Make sure that the colour-coded cap fits firmly into place Getting Started Getting Started Priming Innovo How to prime your InnovoPriming Innovo Choosing your dose Changing a dose Cancelling a doseMaking the injection Making the Injection Checking your previous injection Checking Your Previous Injection Subsequent injections Subsequent Injections What to do when Penfill is nearly empty What to do When Penfill is Changing Penfill Function check What do I do if...? Priming No insulin appears when I try to prime InnovoWhat do I do IF...? Injection Push button blocks during the injection Insulin is delivered when I turn the dose selectorChanging Penfill Cannot open the slide Storage and handling How to store and look after your Innovo insulin doserRemember CleaningDisplay test Display InformationDialling a dose Flashing display During deliveryAfter delivery Previous injectionÆImportant information Important Information 0088

510620 specifications

Novo Nordisk 510620 is a cutting-edge medication developed by the renowned healthcare company Novo Nordisk, which specializes in diabetes care and other chronic diseases. As a part of Novo Nordisk's innovative product portfolio, 510620 is particularly aimed at addressing the needs of patients with type 2 diabetes, a condition that affects millions worldwide.

One of the main features of Novo Nordisk 510620 is its formulation as a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone that plays a crucial role in glucose metabolism. By mimicking the action of this hormone, 510620 stimulates insulin secretion in response to meals, inhibits glucagon release, and promotes satiety. This multi-faceted approach not only helps in lowering blood sugar levels but also aids in weight management, making it particularly suitable for overweight individuals with type 2 diabetes.

In terms of technology, Novo Nordisk 510620 utilizes a novel delivery system that enhances the bioavailability and stability of the active ingredient. This innovative technology involves an injectable formulation that is designed for easy administration, with pre-filled pens that allow patients to self-inject the medication comfortably. The convenience of the delivery system assists in improving patient adherence to treatment protocols, an essential factor in managing chronic conditions such as diabetes.

Another characteristic of Novo Nordisk 510620 is its cardiovascular benefits. Clinical studies have shown that patients using this medication not only achieve better glycemic control but also experience a reduction in the risk of major cardiovascular events. This attribute is critical, considering the high prevalence of cardiovascular complications associated with diabetes.

Safety and tolerability are also key aspects of Novo Nordisk 510620. The medication has undergone rigorous clinical trials, which have demonstrated a favorable safety profile, with common side effects being mild to moderate. Regular monitoring and education about potential side effects play a vital role in ensuring that patients can use 510620 effectively.

In summary, Novo Nordisk 510620 represents an advanced treatment option for type 2 diabetes, characterized by its GLP-1 receptor agonist activity, innovative delivery technology, cardiovascular benefits, and strong safety profile. By continually working on research and development, Novo Nordisk aims to improve the quality of life for individuals affected by chronic diseases, making substantial contributions to the field of diabetes management.